Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by Needham & Company LLC

Esperion Therapeutics (NASDAQ:ESPRGet Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 292.16% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.33.

Read Our Latest Research Report on Esperion Therapeutics

Esperion Therapeutics Stock Down 13.9 %

Shares of NASDAQ ESPR opened at $2.04 on Tuesday. The firm’s 50-day moving average price is $2.31 and its 200-day moving average price is $2.07. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.40. The company has a market cap of $386.38 million, a PE ratio of -0.96 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the firm posted ($0.76) EPS. As a group, equities research analysts anticipate that Esperion Therapeutics will post -0.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ESPR. Herbst Group LLC purchased a new stake in shares of Esperion Therapeutics in the 1st quarter worth $28,000. Chicago Partners Investment Group LLC purchased a new stake in Esperion Therapeutics in the third quarter worth about $29,000. Private Portfolio Partners LLC purchased a new stake in Esperion Therapeutics in the fourth quarter worth about $30,000. CVI Holdings LLC bought a new position in shares of Esperion Therapeutics in the first quarter worth about $37,000. Finally, Simplicity Wealth LLC purchased a new position in shares of Esperion Therapeutics during the 1st quarter valued at about $44,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Stories

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with's FREE daily email newsletter.